Prograf Antitrust

DEFENDANT NAME: Astellas Pharma US LLC
STOCK SYMBOL:
CASE NUMBER: 1:11-md-02242
CASE NAME:
COURT: U.S. District Court for the District of Massachusetts
STATUS: Settled
CLASS PERIOD:
LEAD PLAINTIFF DEADLINE:
DATE FILED: 06/03/11
COURT LOCATION:
RELATED DOCUMENTS:
CONTACT:

In April 2015, Hagens Berman, as court-appointed co-lead class counsel, moved for final approval of a $98 million class settlement for direct purchasers in the Prograf antitrust MDL. The direct purchaser class plaintiffs allege Astellas submitted a sham petition to the U.S. Food and Drug Administration to delay approval of generic versions of the immunosuppressant Prograf.

The antitrust MDL, which was first consolidated in June 2011, alleged that Astellas violated antitrust laws by filing petition with the FDA as a means of delaying entry of a generic version of Prograf, a drug used to prevent organ rejection by kidney, liver, heart and lung transplant patients.

--

The Prograf Antitrust Class Action Lawsuit is In Re: Prograf Antitrust Litigation, MDL No. 2242, U.S. District for the District of Massachusetts.


Hagens Berman purchases advertisements on search engines, social media sites and other websites. Transmission of the information contained or available through this website is not intended to create, and receipt does not constitute, an attorney-client relationship. If you seek legal advice or representation by Hagens Berman, you must first enter a formal agreement. All information contained in any transmission is confidential and Hagens Berman agrees to protect information against unauthorized use, publication or disclosure. This site is regulated by the Washington Rules of Professional Conduct.

Back to all cases

Case videos

Case Gallery

Case Timeline

05/21/15: Case Settled

Final approval of a $98 million class settlement for direct purchasers.

Related News